Mexico Angioplasty Balloons Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF MEXICO ANGIOPLASTY BALLOONS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.8 MARKET END USER COVERAGE GRID

2.9 SECONDARY SOURCES

2.1 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.1.1 POLITICAL FACTORS

4.1.2 ECONOMIC FACTORS

4.1.3 SOCIAL FACTORS

4.1.4 TECHNOLOGICAL FACTORS

4.1.5 ENVIRONMENTAL FACTORS

4.1.6 LEGAL FACTORS

4.2 PATENT ANALYSIS

4.2.1 PATENT QUALITY AND STRENGTH

4.2.2 PATENT FAMILIES

4.2.3 LICENSING AND COLLABORATIONS

4.2.4 REGIONAL PATENT LANDSCAPE

4.2.5 IP STRATEGY AND MANAGEMENT

4.2.6 HISTORICAL & FUTURE OUTLOOK

4.3 COMPANY EVALUATION QUADRANT

4.4 COST ANALYSIS BREAKDOWN

4.5 EPIDEMIOLOGY

4.5.1 INCIDENCE OF ALL BY GENDER

4.5.2 TREATMENT RATE

4.5.3 MORTALITY RATE

4.5.4 PATIENT TREATMENT SUCCESS RATES

4.5.5 CONCLUSION

4.6 INDUSTRY INSIGHTS

4.6.1 MICRO AND MACRO ECONOMIC FACTORS

4.6.2 PENETRATION AND GROWTH PROSPECT MAPPING

4.7 OPPORTUNITY MAP ANALYSIS

4.7.1 HIGH-GROWTH PRODUCT SEGMENTS AND TECHNOLOGY ADVANCEMENT

4.7.2 EXPANDING ACCESS IN TIER II AND TIER III CITIES

4.7.3 PUBLIC PROCUREMENT AND INSTITUTIONAL DEMAND

4.7.4 REGULATORY EVOLUTION AND MARKET ENTRY PATHWAYS

4.7.5 DISTRIBUTION AND HOSPITAL PROCUREMENT MARKUPS

4.7.6 CONCLUSION

4.8 WAR-DRIVEN DISRUPTION IN SUPPLY CHAIN, GEOGRAPHIC FOOTPRINTS, STRUCTURAL CHANGES AND ADAPTIVE STRATEGIES

4.8.1 SUPPLY CHAIN RESILIENCE

4.8.1.1 DIVERSIFICATION OF CRITICAL MEDICAL DEVICE COMPONENT SUPPLIERS

4.8.1.2 ESTABLISHMENT OF REGIONAL MEDICAL DEVICE MANUFACTURING HUBS

4.8.1.3 STRATEGIC STOCKPILING OF CRITICAL DEVICE COMPONENTS

4.8.1.4 DEVELOPMENT OF ALTERNATIVE LOGISTICS ROUTES

4.8.1.5 STRATEGIC PARTNERSHIPS WITH CONTRACT MANUFACTURERS

4.8.1.6 EXPANSION OF MANUFACTURING AND ASSEMBLY CAPABILITIES

4.8.2 ENERGY & MANUFACTURING OPERATIONAL COST RISK

4.8.2.1 RISING ENERGY COSTS IN DEVICE MANUFACTURING

4.8.2.2 INCREASED COSTS FOR MANUFACTURING

4.8.2.3 LONG-TERM ENERGY PROCUREMENT STRATEGIES

4.8.2.4 ADOPTION OF ENERGY-EFFICIENT MANUFACTURING TECHNOLOGIES

4.8.2.5 DEPLOYMENT OF ROBOTICS AND AUTOMATED PRODUCTION LINES

4.8.2.6 INTEGRATION OF RENEWABLE ENERGY IN MEDTECH FACILITIES

4.8.3 GEOGRAPHIC FOOTPRINT REASSESSMENT

4.8.3.1 EXPANSION OF MANUFACTURING IN POLITICALLY STABLE REGIONS

4.8.3.2 DIVERSIFICATION OF GLOBAL MANUFACTURING BASES

4.8.3.3 RELOCATION OF CRITICAL COMPONENT PRODUCTION

4.8.3.4 EXPANSION OF MEDTECH MANUFACTURING IN EMERGING MARKETS

4.8.3.5 ESTABLISHMENT OF REGIONAL DISTRIBUTION AND SERVICE HUBS

4.8.4 SCENARIO PLANNING & RISK MANAGEMENT

4.8.4.1 DEVELOPMENT OF SUPPLY CHAIN CONTINGENCY PLANS

4.8.4.2 MULTI-SOURCE PROCUREMENT STRATEGIES

4.8.4.3 GOVERNMENT AND HEALTH SYSTEM COLLABORATIONS

4.8.4.4 DEPLOYMENT OF PREDICTIVE SUPPLY CHAIN ANALYTICS

4.8.4.5 GEOGRAPHIC FOOTPRINT REASSESSMENT

4.8.5 CASH & FINANCIAL PROTECTION

4.8.5.1 STRENGTHENING CAPITAL RESERVES

4.8.5.2 DIVERSIFICATION OF MEDTECH REVENUE STREAMS

4.8.5.3 INVESTMENTS IN DOMESTIC DEVICE MANUFACTURING

4.8.5.4 GOVERNMENT INCENTIVES AND PUBLIC-PRIVATE PARTNERSHIPS

4.8.5.5 LONG-TERM PROCUREMENT AGREEMENTS WITH HEALTHCARE SYSTEMS

4.8.6 DATA PROTECTION

4.8.6.1 DATA PROTECTION FRAMEWORKS FOR MEDICAL DEVICES

4.8.6.2 PROTECTION OF PATIENT AND DEVICE DATA

4.8.6.3 SECURE CLOUD INFRASTRUCTURE FOR DEVICE MANAGEMENT

4.8.6.4 AI-DRIVEN THREAT DETECTION

4.8.6.5 COMPLIANCE WITH MEDICAL DEVICE DATA REGULATIONS

4.8.7 NEW BUSINESS AND EMERGING REVENUE OPPORTUNITIES & FUTURE OUTLOOK

4.9 HEALTHCARE ECONOMY

4.9.1 HEALTHCARE EXPENDITURE

4.9.2 CAPITAL EXPENDITURE

4.9.3 CAPEX TRENDS

4.9.4 CAPEX ALLOCATION

4.9.5 FUNDING SOURCES

4.9.6 INDUSTRY BENCHMARKS

4.9.7 HEALTHCARE EXPENDITURE IN OVERALL GDP

4.9.8 HEALTHCARE SYSTEM STRUCTURE

4.9.9 GOVERNMENT POLICIES

4.9.10 ECONOMIC DEVELOPMENT

4.1 REIMBURSEMENT FRAMEWORK

4.10.1 PUBLIC HEALTHCARE REIMBURSEMENT MECHANISM

4.10.2 PRIVATE INSURANCE AND OUT-OF-POCKET REIMBURSEMENT

4.10.3 CODING, PRICING, AND DRG-LIKE STRUCTURES

4.10.4 ROLE OF REGULATORY AND HEALTH TECHNOLOGY ASSESSMENT (HTA) BODIES

4.10.5 CHALLENGES IN THE REIMBURSEMENT ENVIRONMENT

4.10.6 OPPORTUNITIES AND FUTURE OUTLOOK

4.10.7 CONCLUSION

4.11 SUPPLY CHAIN ECOSYSTEM

4.11.1 PROMINENT COMPANIES

4.11.2 SMALL & MEDIUM SIZE COMPANIES

4.11.3 END USERS

4.12 TECHNOLOGY ROADMAP

4.12.1 MATERIAL SCIENCE AND BALLOON COMPLIANCE ENGINEERING

4.12.2 DRUG-COATED BALLOON TECHNOLOGY INTEGRATION

4.12.3 SCORING AND CUTTING BALLOON INNOVATIONS

4.12.4 SURFACE COATING AND LUBRICITY ENHANCEMENT TECHNOLOGIES

4.12.5 INTEGRATION WITH IMAGING AND PRECISION-GUIDED INTERVENTIONS

4.12.6 MANUFACTURING AUTOMATION AND QUALITY STANDARDIZATION

4.12.7 FUTURE TECHNOLOGY TRAJECTORY IN THE MEXICAN MARKET

5 INNOVATION TRACKER AND STRATEGIC ANALYSIS

5.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS

5.1.1 JOINT VENTURES

5.1.2 MERGERS AND ACQUISITIONS

5.1.3 LICENSING AND PARTNERSHIP

5.1.4 TECHNOLOGY COLLABORATIONS

5.1.5 STRATEGIC DIVESTMENTS

5.2 NUMBER OF PRODUCTS IN DEVELOPMENT

5.3 STAGE OF DEVELOPMENT

5.4 TIMELINES AND MILESTONES

5.5 INNOVATION STRATEGIES AND METHODOLOGIES

5.6 RISK ASSESSMENT AND MITIGATION

5.7 FUTURE OUTLOOK

6 TARIFFS & IMPACT

6.1 CURRENT TARIFF RATE (S) IN TOP-5 COUNTRY MARKETS

6.2 OUTLOOK: LOCAL PRODUCTION VERSUS IMPORT RELIANCE

6.3 VENDOR SELECTION CRITERIA DYNAMICS

6.4 IMPACT ON SUPPLY CHAIN

6.4.1 RAW MATERIAL PROCUREMENT

6.4.2 MANUFACTURING AND PRODUCTION

6.4.3 LOGISTICS AND DISTRIBUTION

6.4.4 PRICE PITCHING AND POSITION OF MARKET

6.5 INDUSTRY PARTICIPANTS: PROACTIVE MOVES

6.5.1 SUPPLY CHAIN OPTIMIZATION

6.5.2 JOINT VENTURE ESTABLISHMENTS

6.6 IMPACT ON PRICES

6.7 REGULATORY INCLINATION

6.7.1 GEOPOLITICAL SITUATION

6.7.2 TRADE PARTNERSHIPS BETWEEN COUNTRIES

6.7.2.1 FREE TRADE AGREEMENTS

6.7.3 ALLIANCES ESTABLISHEMENTS

6.7.4 STATUS ACCREDITION (INCLUDING MFTN)

6.7.5 DOMESTIC COURSE OF CORRECTION

6.7.5.1 INCENTIVE SCHEMES TO BOOST PRODUCTION OUTPUTS

6.7.5.2 ESTABLISHMENT OF SPECIAL ECONOMIC ZONES/INDUSTRIAL PARKS

6.8 PRICE INDEX

7 REGULATORY COMPLIANCE

7.1 REGULATORY AUTHORITIES

7.2 REGULATORY CLASSIFICATIONS

7.3 REGULATORY SUBMISSIONS

7.4 INTERNATIONAL HARMONIZATION

7.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS

7.6 REGULATORY CHALLENGES AND STRATEGIES

8 MARKET OVERVIEW

8.1 DRIVERS

8.1.1 RISING PREVALENCE OF CARDIOVASCULAR DISEASES IN MEXICO

8.1.2 GROWING PUBLIC AWARENESS OF MINIMALLY INVASIVE SURGICAL TECHNIQUES

8.1.3 RISING HEALTHCARE EXPENDITURE AND INSURANCE PENETRATION

8.2 RESTRAINTS

8.2.1 HIGH COST OF DRUG-COATED AND SCORING BALLOON TECHNOLOGIES

8.2.2 LIMITED REIMBURSEMENT COVERAGE FOR ADVANCED ANGIOPLASTY PROCEDURES

8.3 OPPORTUNITIES

8.3.1 INTEGRATION OF AI-BASED IMAGING IN ANGIOPLASTY PROCEDURES

8.3.2 INCREASING ADOPTION OF HYBRID BALLOON-STENT PROCEDURES

8.4 CHALLENGES

8.4.1 SUPPLY CHAIN DISRUPTIONS FOR IMPORTED BALLOON DEVICES

8.4.2 REGULATORY COMPLEXITY FOR INTRODUCING NEW BALLOON TECHNOLOGIES

9 MEXICO ANGIOPLASTY BALLOONS MARKET, BY TYPE

9.1 OVERVIEW

9.2 PLAIN OLD BALLOON ANGIOPLASTY

9.3 DRUG-COATED BALLOON (DCB)

9.4 SCORING BALLOONS

9.5 CUTTING BALLOONS

9.6 STENT GRAFT BALLOON CATHETER

9.7 OTHERS

9.8 MEXICO PLAIN OLD BALLOON ANGIOPLASTY IN ANGIOPLASTY BALLOONS MARKET, BY PRESSURE CAPABILITY, 2018-2033 (USD THOUSAND)

9.8.1 HIGH-PRESSURE BALLOONS

9.8.2 ULTRA-HIGH PRESSURE BALLOONS

9.8.3 LOW-PRESSURE BALLOONS

9.9 MEXICO PLAIN OLD BALLOON ANGIOPLASTY IN ANGIOPLASTY BALLOONS MARKET, BY BALLOON TYPE, 2018-2033 (USD THOUSAND)

9.9.1 NON-COMPLIANT

9.9.2 SEMI-COMPLIANT

9.9.3 COMPLIANT

9.1 MEXICO PLAIN OLD BALLOON ANGIOPLASTY IN ANGIOPLASTY BALLOONS MARKET, BY LESION TYPE, 2018-2033 (USD THOUSAND)

9.10.1 SOFT LESIONS

9.10.2 FIBROTIC LESIONS

9.10.3 CALCIFIED LESIONS

9.11 MEXICO PLAIN OLD BALLOON ANGIOPLASTY IN ANGIOPLASTY BALLOONS MARKET, BY LENGTH, 2018-2033 (USD THOUSAND)

9.11.1 MEDIUM (10–20 MM)

9.11.2 LONG (>20 MM)

9.11.3 SHORT (<10 MM)

9.12 MEXICO DRUG-COATED BALLOON (DCB) IN ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.12.1 PACLITAXEL-COATED BALLOONS

9.12.2 SIROLIMUS-COATED BALLOONS

9.12.3 COMBINATION DRUG COATINGS

9.12.4 OTHERS

9.13 MEXICO DRUG-COATED BALLOON (DCB) IN ANGIOPLASTY BALLOONS MARKET, BY DRUG DELIVERY MECHANISM, 2018-2033 (USD THOUSAND)

9.13.1 POLYMER-BASED COATING

9.13.2 POLYMER-FREE COATING

9.13.3 MICRO-RESERVOIR DELIVERY

9.14 MEXICO DRUG-COATED BALLOON (DCB) IN ANGIOPLASTY BALLOONS MARKET, BY LENGTH, 2018-2033 (USD THOUSAND)

9.14.1 MEDIUM (10–20 MM)

9.14.2 LONG (>20 MM)

9.14.3 SHORT (<10 MM)

9.15 MEXICO DRUG-COATED BALLOON (DCB) IN ANGIOPLASTY BALLOONS MARKET, BY BALLOON TYPE, 2018-2033 (USD THOUSAND)

9.15.1 SEMI-COMPLIANT

9.15.2 NON-COMPLIANT

9.15.3 COMPLIANT

9.16 MEXICO SCORING BALLOONS IN ANGIOPLASTY BALLOONS MARKET, BY TECHNOLOGY, 2018-2033 (USD THOUSAND)

9.16.1 WIRE-BASED SCORING BALLOONS

9.16.2 HELICAL SCORING BALLOONS

9.16.3 CAGE-BASED SCORING SYSTEMS

9.16.4 OTHERS

9.17 MEXICO SCORING BALLOONS IN ANGIOPLASTY BALLOONS MARKET, BY BALLOON TYPE, 2018-2033 (USD THOUSAND)

9.17.1 NON-COMPLIANT

9.17.2 SEMI-COMPLIANT

9.17.3 COMPLIANT

9.18 MEXICO CUTTING BALLOONS IN ANGIOPLASTY BALLOONS MARKET, BY BLADE DESIGN, 2018-2033 (USD THOUSAND)

9.18.1 MICROTOME BLADES

9.18.2 LONGITUDINAL SCORING BLADES

9.19 MEXICO CUTTING BALLOONS IN ANGIOPLASTY BALLOONS MARKET, BY BALLOON TYPE, 2018-2033 (USD THOUSAND)

9.19.1 NON-COMPLIANT

9.19.2 SEMI-COMPLIANT

9.19.3 COMPLIANT

9.2 MEXICO STENT GRAFT BALLOON CATHETER IN ANGIOPLASTY BALLOONS MARKET, BY BALLOON TYPE, 2018-2033 (USD THOUSAND)

9.20.1 NON-COMPLIANT

9.20.2 SEMI-COMPLIANT

9.20.3 COMPLIANT

10 MEXICO ANGIOPLASTY BALLOONS MARKET, BY MATERIAL

10.1 OVERVIEW

10.2 NYLON

10.3 POLYURETHANE

10.4 SILICONE URETHANE CO-POLYMERS

10.5 POLYETHYLENE

10.6 OTHERS

11 MEXICO ANGIOPLASTY BALLOONS MARKET, BY BALLOON TYPE

11.1 OVERVIEW

11.2 NON-COMPLIANT

11.3 SEMI-COMPLIANT

11.4 COMPLIANT

12 MEXICO ANGIOPLASTY BALLOONS MARKET, BY DISEASE INDICATION

12.1 OVERVIEW

12.2 CORONARY ANGIOPLASTY

12.3 PERIPHERAL ANGIOPLASTY

12.4 CAROTID ANGIOPLASTY

12.5 RENAL ARTERY ANGIOPLASTY

12.6 VENOUS ANGIOPLASTY

12.7 OTHERS

13 MEXICO ANGIOPLASTY BALLOONS MARKET, BY END USER

13.1 OVERVIEW

13.2 HOSPITALS

13.3 CATH LABS

13.4 AMBULATORY SURGERY CENTERS (ASCS)

13.5 SPECIALTY CLINICS

13.6 DIAGNOSTIC CENTERS

13.7 OTHERS

13.8 MEXICO HOSPITALS IN ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

13.8.1 PUBLIC

13.8.2 PRIVATE

13.9 MEXICO PUBLIC IN ANGIOPLASTY BALLOONS MARKET, BY TIER, 2018-2033 (USD THOUSAND)

13.9.1 TIER I

13.9.2 TIER II

13.9.3 TIER III

13.1 MEXICO PRIVATE IN ANGIOPLASTY BALLOONS MARKET, BY TIER, 2018-2033 (USD THOUSAND)

13.10.1 TIER I

13.10.2 TIER II

13.10.3 TIER III

14 MEXICO ANGIOPLASTY BALLOONS MARKET, BY DISTRIBUTION CHANNEL

14.1 OVERVIEW

14.2 DIRECT TENDER

14.3 RETAIL SALES

14.4 ONLINE SALES

14.5 OTHERS

15 MEXICO ANGIOPLASTY BALLOONS MARKET

15.1 COMPANY SHARE ANALYSIS: MEXICO

16 SWOT ANALYSIS

16.1 DBMR ANALYSIS

17 COMAPANY PROFILES MANUFACTURERS

17.1 BOSTON SCIENTIFIC CORPORATION

17.1.1 COMPANY SNAPSHOT

17.1.2 REVENUE ANALYSIS

17.1.3 PRODUCT PORTFOLIO

17.1.4 RECENT DEVELOPMENT

17.2 MEDTRONIC.

17.2.1 COMPANY SNAPSHOT

17.2.2 REVENUE ANALYSIS

17.2.3 PRODUCT PORTFOLIO

17.2.4 RECENT DEVELOPMENT

17.3 ABBOTT.

17.3.1 COMPANY SNAPSHOT

17.3.2 REVENUE ANALYSIS

17.3.3 PRODUCT PORTFOLIO

17.3.4 RECENT DEVELOPMENT

17.4 TERUMO CORPORATION.

17.4.1 COMPANY SNAPSHOT

17.4.2 REVENUE ANALYSIS

17.4.3 PRODUCT PORTFOLIO

17.4.4 RECENT DEVELOPMENT

17.5 B. BRAUN MEDICAL PVT. LTD.

17.5.1 COMPANY SNAPSHOT

17.5.2 PRODUCT PORTFOLIO

17.5.3 RECENT DEVELOPMENT

17.6 BIOTRONIK.

17.6.1 COMPANY SNAPSHOT

17.6.2 PRODUCT PORTFOLIO

17.6.3 RECENT DEVELOPMENT

17.7 COOK.

17.7.1 COMPANY SNAPSHOT

17.7.2 PRODUCT PORTFOLIO

17.7.3 RECENT DEVELOPMENT

17.8 CORDIS.

17.8.1 COMPANY SNAPSHOT

17.8.2 PRODUCT PORTFOLIO

17.8.3 RECENT DEVELOPMENT

17.9 MICROPORT SCIENTIFIC CORPORATION

17.9.1 COMPANY SNAPSHOT

17.9.2 REVENUE ANALYSIS

17.9.3 PRODUCT PORTFOLIO

17.9.4 RECENT DEVELOPMENT

17.1 ORBUSNEICH MEDICAL GROUP HOLDINGS LIMITED.

17.10.1 COMPANY SNAPSHOT

17.10.2 PRODUCT PORTFOLIO

17.10.3 RECENT DEVELOPMENT

17.11 TELEFLEX INCORPORATED.

17.11.1 COMPANY SNAPSHOT

17.11.2 REVENUE ANALYSIS

17.11.3 PRODUCT PORTFOLIO

17.11.4 RECENT DEVELOPMENT

18 COMAPANY PROFILES - DISTRIBUTORS

18.1 CARDINAL HEALTH.

18.1.1 COMPANY SNAPSHOT

18.1.2 REVENUE ANALYSIS

18.1.3 PRODUCT PORTFOLIO

18.1.4 RECENT DEVELOPMENT

18.2 ENDOMÉDICA SA DE CV.

18.2.1 COMPANY SNAPSHOT

18.2.2 PRODUCT PORTFOLIO

18.2.3 RECENT DEVELOPMENT

18.3 GETINGE

18.3.1 COMPANY SNAPSHOT

18.3.2 REVENUE ANALYSIS

18.3.3 PRODUCT PORTFOLIO

18.3.4 RECENT DEVELOPMENT

18.4 LEVBETH MEDICAL SA DE CV.

18.4.1 COMPANY SNAPSHOT

18.4.2 PRODUCT PORTFOLIO

18.4.3 RECENT DEVELOPMENT

18.5 MEDSTENT, S.A. DE C.V.

18.5.1 COMPANY SNAPSHOT

18.5.2 PRODUCT PORTFOLIO

18.5.3 RECENT DEVELOPMENT

19 COMAPANY PROFILES - COST PLAYERS

19.1 SMT.

19.1.1 COMPANY SNAPSHOT

19.1.2 PRODUCT PORTFOLIO

19.1.3 RECENT DEVELOPMENT

19.2 INVAMED.

19.2.1 COMPANY SNAPSHOT

19.2.2 PRODUCT PORTFOLIO

19.2.3 RECENT DEVELOPMENT

20 QUESTIONNAIRE

21 RELATED REPORTS